The expectation is that COVID-19 will eventually settle into a winter seasonal pattern like other coronaviruses, but the past ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Diagnostics' progress on their PCR platform, with key trials in 2025 and commercialization plans by 2026, targeting U.S. and global markets.

Key Points GAAP revenue jumped 413% year over year to $11.8 million in Q2 2025, but fell far short of analyst estimates, with GAAP revenue of $11.8 million missing the consensus of $23.2 million by 49 ...

Seasonal shifts are driving unusual surges in respiratory illnesses in 2025, with COVID-19, influenza, and RSV showing new ...

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory ...

Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV.

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.